bullish
Samsung BioLogics (207940 KS): Korea FSC Ruling Summary & Clarifications
808 Views13 Jul 2018 01:56
This Korea FSC's final ruling on Samsung Biologics Co., Ltd (207940 KS)'s accounting fraud case is very confusing. So, let me walk you...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Korea Top Conglomerates Synthetic Pair Trading20 May 2021
- Samsung Biologics Contract Manufacturing Deal with Moderna for COVID-19 Vaccines: Key Takeaways14 May 2021
- Samsung Biologics CMO Deal Noise & Samsung C&T Synthetic Subsidiary Stub Trade13 May 2021
- Samsung BioLogics (207940 KS): Korea FSC Ruling Summary & Clarifications13 Jul 2018
- Biogen Exercises Samsung Bioepis Call Option - Summary & Implications30 Jun 2018
- FSS Vs. Samsung BioLogics - Latest Situation Update10 May 2018
- Samsung BioLogics - Market Sentiment Assessment05 May 2018
x